等待开盘 11-29 09:30:00 美东时间
ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) shares are trading higher Thursday. The move marks a rebound in the stock following a recent drop in price.
Wedbush analyst Andreas Argyrides maintains ARS Pharmaceuticals (NASDAQ:SPRY) with a Outperform and lowers the price target from $15 to $5.
U.S. stocks traded mostly higher toward the end of trading, with the Dow Jones gaining around 200 points on Wednesday. The Dow traded up 0.59% to 34,720.69 while the NASDAQ fell 0.07% to 13,668.37. The S&P 500 also rose, gaining, 0.17% to 4,451.42.
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite turning lower on Wednesday. The Dow traded up 0.56% to 34,711.50 while the NASDAQ fell 0.17% to 13,654.54. The S&P 500 also rose, gaining, 0.21% to 4,453.12.
Upgrades For Regency Centers Corp (NASDAQ:REG), Argus Research upgraded the pre...
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 150 points on Tuesday. The Dow traded up 0.47% to 34,680.84 while the NASDAQ rose 0.26% to 13,713.13. The S&P 500 also rose, gaining, 0.37% to 4,460.20.
The FDA issued a Complete Response Letter regarding ARS Pharmaceuticals Inc's (NASDAQ: SPRY) New Drug Application (NDA) for neffy (epinephrine nasal spray) in the treatment of Allergic Reactions (Type I), including anaphylaxis (fatal allergic reaction) for
Joshua Brown of Ritholtz Wealth Management recommends selling shares of Instacart (Maplebear Inc.) (NYSE: CART), which just went public.
EXAI: 36% | Exscientia Announces AI Drug Discovery Collaboration with Merck KGaA, Darmstadt, Germany SPRY: -66% | FDA Issues Complete Response Letter For ARS Pharma's neffy® Epinephrine Nasal